Clinical trials: Non-Alcoholic SteatoHepatitis (NASH)
Non-Alcoholic Fatty Liver Disease
Effects of Time-restricted Hypocaloric Diet in Patients with NAFLD
The effects of a time-restricted hypocaloric Mediterranean type diet compared to a conventional hypocaloric Mediterranean type diet on blood glucose metabolism and liver steatosis in people with non-alcoholic fatty liver disease…
- Trial name
- NCT05866744
- Testing
- Early Time-Restricted Feeding Plus Hypocaloric Mediterranean Diet, Late Time-Restricted Feeding Plus Hypocaloric Mediterranean Diet, Hypocaloric Mediterranean Diet Without Time Restriction In Feeding
- Where
- 2 sites in Greece
- Volunteers
- 59 people
- Sponsor
- Agricultural University of Athens
Obesity, Childhood, NAFLD
Can Fecal Calprotectin Be Used as a Biomarker of Non-alcoholic Fatty Liver Disease In Obese Adolescents?
The incidence of non-alcoholic fatty liver disease (NAFLD) is increasing with obesity, and it is believed that ongoing inflammation in obesity and alterations in the enterohepatic axis contribute to this process.
- Trial name
- NCT06229184
- Testing
- Fecal Calprotectin Test
- Where
- Turkey (Türkiye)
- Volunteers
- 41 people, healthy volunteers welcome
- Sponsor
- Sisli Hamidiye Etfal Training and Research Hospital
Non-Alcoholic Fatty Liver Disease
The Effect of an RBAC Supplement (BRM4) on NAFLD
The purpose of this study is to investigate the effects of Rice Bran Arabinoxylan Compound (RBAC) on outcome variables in persons with non-alcoholic fatty liver disease (NAFLD).
- Trial name
- NCT02568787
- Testing
- rice bran arabinoxylan compound (RBAC)
- Where
- United States
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- University of Miami
Nonalcoholic Fatty Liver, Nonalcoholic Steatohepatitis
The Liver Health Study for Patients with NAFLD
The study will investigate whether the level of fat stored in the liver is related to the liver's ability to burn fat.
- Conditions
- Nonalcoholic Fatty Liver, Nonalcoholic Steatohepatitis, Obesity
- Trial name
- NCT03151798
- Testing
- Phase II: Lifestyle treatment, Phase II: Control treatment, Phase I: Observational studies
- Where
- United States
- Volunteers
- 336 people
- Sponsor
- University of Missouri-Columbia
Fatty Liver Disease, Fatty Liver
Impact of Time-restricted Feeding in NAFLD
This is a randomised controlled study of patients with Non-Alcoholic Fatty Liver Disease (NAFLD). Patients will be trained according to the 10 rules of a healthy nutrition according to the German Association for Nutrition (DGE).
- Conditions
- Fatty Liver Disease, Fatty Liver, Fatty Liver, Nonalcoholic
- Trial name
- NAFLD-TRF (NCT05220956)
- Testing
- Intermittent fasting, DGE diet
- Where
- Germany
- Volunteers
- 100 people
- Sponsor
- Johannes Gutenberg University Mainz
Colorectal Neoplasms, Nonalcoholic Fatty Liver Disease
Study of the Association of Nonalcoholic Fatty Liver Disease With Colorectal Malignant Neoplasm
The aim of this sudy is to investigate the prevalence of colorectal cancer (CRC) in patients with nonalcoholic fatty liver disease (NAFLD) and evaluate whether NAFLD is a risk factor for CRC.
- Trial name
- NWC (NCT01657773)
- Testing
- Ultrasound examination and Colonoscopy examination
- Where
- China
- Volunteers
- 2,315 people, healthy volunteers welcome
- Sponsor
- Wenzhou Medical University
Insulin Resistance, Hyperinsulinemia
Human Models of Selective Insulin Resistance: Pancreatic Clamp
This is a single-center, prospective, randomized, controlled (crossover) clinical study designed to investigate the impact of lowering insulin levels on hepatic glucose production (HGP) vs de novo lipogenesis (DNL) in people with…
- Conditions
- Insulin Resistance, Hyperinsulinemia, Metabolic Dysfunction Associated Steatotic Liver Disease, Non-Alcoholic Fatty Liver Disease
- Trial name
- NCT06558422
- Testing
- Insulin human, Octreotide Acetate, Glucagon
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Columbia University
Nonalcoholic Steatohepatitis
CM-101 in NASH Patients - The SPLASH Study
This phase 2a study is a multi-center, double-blind randomized, placebo-controlled study. The study is designed to determine the safety and tolerability of the anti-human CCL24 monoclonal antibody CM-101 in adult patients with…
- Trial name
- NCT05824156
- Testing
- 5 mg/kg CM-101
- Where
- 9 sites in Israel
- Volunteers
- 23 people
- Sponsor
- ChemomAb Ltd.
Psoriatic Arthritis, Osteoarthitis
CARTIZ Registry: Cartilage, Arthropathy and Imaging Under Tirzepatide in Zone-stratified Cohorts - A Four-Institute Mexican Observational Registry
CARTIZ is a prospective observational clinical registry of adults in Mexico receiving tirzepatide (a dual GLP-1/GIP receptor agonist) under an independent clinical indication - typically type 2 diabetes, insulin resistance…
- Conditions
- Psoriatic Arthritis, Osteoarthitis, Knee, Diabetes (DM)
- Trial name
- CARTIZ (NCT07567378)
- Testing
- Tirzepatide
- Where
- Mexico
- Volunteers
- 30 people
- Sponsor
- JULIO GRANADOS MONTIEL
NASH
A Clinical Trial of BGT-002 Tablets in Subjects With Nonalcoholic Steatohepatitis
This study is a single-center, randomized, double-blind, multiple ascending doses (MAD), placebo-controlled phase Ib/IIa clinical trial of BGT-002 Tablets in subjects with NASH to evaluate the safety, tolerability…
- Trial name
- NCT06491576
- Testing
- BGT-002
- Where
- China
- Volunteers
- 48 people
- Sponsor
- Burgeon Therapeutics Co., Ltd.
Fatty Liver Disease, Steatohepatitis, Nonalcoholic
Clinical Study Evaluating the Safety and Efficacy of Esomeprazole in Treatment of Non-alcoholic Steatohepatitis
The aim of the study is to test the implication of esomeprazole as a possible potential therapy for patients with NASH through evaluating its effect on ultrasound and fibrosis risk scores, serum levels of liver fibrosis…
- Trial name
- NCT06302049
- Testing
- Esomeprazole
- Where
- Egypt
- Volunteers
- 46 people
- Sponsor
- Sadat City University
NAFLD
The Effects of Dihydromiricetin on MASLD
The global wave of obesity has affected dramatically the incidence of non-alcoholic fatty liver disease (NAFLD) making it the leading cause of liver disease in the western world.
- Trial name
- NCT05052515
- Testing
- Dihydromiricetin, Vitamin C, E and Choline
- Where
- Greece
- Volunteers
- 55 people
- Sponsor
- University of Athens
Nonalcoholic Steatohepatitis
Safety and Efficacy of Solithromycin in the Treatment of Nonalcoholic Steatohepatitis Without Cirrhosis
The purpose of this study is to evaluate the effects of solithromycin on hepatic histology and biomarkers in patients with nonalcoholic steatohepatitis.
- Trial name
- NCT02510599
- Testing
- solithromycin
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Melinta Therapeutics, Inc.
Non-alcoholic Fatty Liver Disease (NAFLD)
Elucidating Hepatic Metabolism in Non-alcoholic Fatty Liver Disease
The goal of this observational, cross-sectional, case-control clinical study is to investigate the metabolic adaptations underlying the progression of nonalcoholic fatty liver disease (NAFLD), and to test the hypothesis that…
- Trial name
- ECHO (NCT06942312)
- Testing
- Ketoisocaproic acid breath test, Ammonium Chloride, Bicarbonate de sodium
- Where
- Finland
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Helsinki University Central Hospital
Metabolic Dysfunction-associated Fatty Liver Disease (MAFLD)
Linzhi Jianghuang Fufang Huoxue Anshen Capsule for Non-alcoholic Fatty Liver
This is a randomized, double-blinded, placebo-controlled clinical trial aimed at evaluating the efficacy and safety of Linzhi Jianghuang Fufang Huoxue Anshen Capsule (LJF) for non-alcoholic fatty liver.
- Trial name
- LJF (NCT07637006)
- Testing
- Linzhi Jianghuang Fufang Huoxue Anshen Capsule (LJF)
- Volunteers
- 180 people
- Sponsor
- Hong Kong Baptist University
Nonalcoholic Steatohepatitis
Phase I Pharmacokinetic Study of HUYPS-1 in Healthy Volunteers
Fasting Period: At least 10 hours prior to dosing until 4 hours post-dose of each study period. Period: 24 hours post dose in each period. Each subject will complete two study periods.
- Trial name
- NCT05983328
- Testing
- HUYPS-1 one tablet, HUYPS-1 nine tablets
- Where
- Taiwan
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Sinew Pharma Inc.
Mafld in Ckd Patients
Association Betweenq MAFLD ( Metabolic Associated Fatty Liver Disease) and Chronic Kidney Disease
Assess frequency of renal affection in mafld
- Trial name
- NCT06135467
- Volunteers
- 150 people
- Sponsor
- Assiut University
Metabolic Syndrome, Fatty Liver Disease
Metabolic Syndrome and Fatty Liver Disease Among Egyptian Patients with Chronic HBV
1. investigate the Prevalence of combined hepatic steatosis in patients with chronic HBV. 2. to evaluate clinical characteristics of chronic HBV patients combined with metabolic syndrome and hepatic steatosis
- Trial name
- NCT06589167
- Volunteers
- 100 people
- Sponsor
- Assiut University
Non-Alcoholic Steatohepatitis (NASH), Type2 Diabetes Mellitus
A Pilot Study to Assess the Safety of Oral Insulin in Patients With Nonalcolholic Steatohepatitis (NASH)
This is an open, pilot study using the oral ORMD-0801 insulin formulation in patients with NASH and confirmed type 2 DM or pre-diabetes.
- Trial name
- NCT02653300
- Testing
- Oral Insulin
- Where
- Israel
- Volunteers
- 10 people
- Sponsor
- Oramed, Ltd.
Metabolic Syndrome, Non Alcoholic Fatty Liver Disease
Glucomannan Effects on Children With Non-alcoholic Fatty Liver Disease
Non-alcoholic fatty liver disease (NAFLD) has reached epidemic proportions and is rapidly becoming the one of most common causes of chronic liver disease in children.
- Conditions
- Metabolic Syndrome, Non Alcoholic Fatty Liver Disease, Insulin Resistance
- Trial name
- GC-NASH (NCT01553500)
- Testing
- glucomannan, lifestyle intervention
- Where
- Italy
- Volunteers
- 66 people
- Sponsor
- Bambino Gesù Hospital and Research Institute